{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-25-000069","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.129283+00:00","generated_at":"2026-05-21T10:21:29.934422+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Centessa Q1 net loss $26.1M; cash $424.9M; OX2R agonist pipeline on track for 2025 data","bullets":["Net loss narrowed to $26.1M from $38.0M in Q1 2024, with no product revenue.","Cash, equivalents and investments totaled $424.9M, expected to fund operations into mid-2027.","R&D expenses increased to $33.4M from $22.7M, driven by pipeline advancement.","ORX750 Phase 2a CRYSTAL-1 study ongoing; data from narcolepsy NT1, NT2 and IH anticipated in 2025.","ORX142 first-in-human studies planned in 2025 with data from sleep-deprived healthy volunteers expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-25-000069","json":"https://secwatch.observer/filing/0001847903-25-000069.json","markdown":"https://secwatch.observer/filing/0001847903-25-000069.md","text":"https://secwatch.observer/filing/0001847903-25-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790325000069/0001847903-25-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790325000069/cnta-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T10:21:29.934422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}